|
Research
Cancer
Clinical Trials:
Glioblastoma Protocols
- LS-P-CENTRIC:
Cilengitide for subjects with newly
diagnosed GBM and methylated MGMT gene
promoter - a multicenter, open-label,
controlled Phase III study, testing
cilengitide in combination with standart
treatment (tem with concomitant radiation
theraphy, following by tem maintenance
therapy) vs. standard treatment alone
Principal Investigator: Suriya
Jeyapalan, MD
Sites: Rhode Island Hospital
- RTOG 0825:
Phase III Double-Blind
Placebo-Controlled Trial of Conventional
Concurrent Chemoradiation and Adjuvant
Temozolomide Plus Bevacizumab Versus
Conventional Concurrent Chemoradiation and
Adjuvant Temozolomide in Patients with Newly
Diagnosed Glioblastoma.
Principal Investigator:
Brigid O'Connor, MD, PhD
Site: Rhode Island Hospital
- RTOG 0929: A
Randomized Phase I/II Study of ABT-888 in
Combination with Temozolomide in Recurrent (Temozolomide
Resistant)
Principal Investigator: Heinrich
Elinzano, MD
Sites: Rhode Island Hospital
For more information
about these clinical trials and how to
participate, please call 401-444-HOPE (4673).
For general information about clinical trials
please visit the
National Cancer Institute.
Other Clinical Trials and
Noteworthy Treatments for Brain Tumors in the
Rhode Island area.
Keywords:
Observation, Radiation, Chemotherapy
Phase: Phase 2
Treatment ID#s:
VT1508 NCT00027846
Age Group: Pediatric
Only
Min Karnofsky
Score: 10: Fatal processes progressing rapidly
Conditions: Newly
Diagnosed: Y
Recurrent: Y
Prior Surgery is Allowed
Prior Radiation is Not Allowed
Prior Chemotherapy is Not Allowed
Patients must be greater than twelve months and
less than twenty one years of age.
Histologically confirmed intracranial ependymoma.
No evidence of spread of disease beyond the
primary site. No prior therapy beyond surgery
and corticosteroids.
Tumor Types:
Ependyoma
Comments: Ependymoma
is a relatively rare type of central nervous
system (CNS) tumor. Standard treatment for
ependymoma is surgical removal followed by post
operative radiation therapy directed at the
primary site. Young children, less than three
years of age, typically have not received
radiation therapy, but instead have received
multi-agent chemotherapy in an effort to delay
radiation therapy. Patients with ependymoma who
have incomplete resections and those who delay
radiation therapy with chemotherapy have poor
overall survival. With the help of the
Children’s Oncology Group (COG), investigators
want to answer important questions with the hope
of improving the outcomes (improved survival
with reduced side effects) for these patients by
increasing the rate of complete resection and by
using conformal radiation therapy for children
older than 12 months of age. Researchers will
investigate the use of chemotherapy in children
with incomplete resections prior to second
surgery, conformal radiation therapy, and no
therapy after surgery for completely resected
supratentorial, differentiated ependymoma For
more information:
www.stjude.org/brain-tumors
Treatment Type:
Chemotherapy
Radiation.
Location:
Rhode Island
Hospital
Sam W. Lew, MD
Providence, RI 02903
401-444-5171
Source:
http://virtualtrials.com/trialdetails2.cfm?id=150801005
Keywords: Stem cell
transplant
Phase: Phase 2
Treatment ID#s:
VT619 NCT00047320
Age Group: Adult and
Pediatric
Min Karnofsky Score:
10: Fatal processes progressing rapidly
Conditions: Newly
Diagnosed: Y
Recurrent: Y
Prior Surgery is Allowed
Prior Radiation is Not Allowed
Prior Chemotherapy is Not Allowed
Tumor Types: Germ
Cell Tumors
Comments: This is a
multi-institutional clinical research study
which is aimed at improving disease-free and
overall survival for patients diagnosed with a
non-germinoma germ cell tumor (NGGCT), a
malignant brain tumor formed by cancerous germ
cells, by using multi-agent chemotherapy
followed by radiotherapy. Patients will
initially receive four 3-week chemotherapy
cycles utilizing a three-drug regimen consisting
of Cisplatin, Etoposide and Ifosfamide. If the
patient has a complete response (CR), i.e.,
complete disappearance of the tumor after these
4 cycles, they will then proceed to radiation
therapy. If there is still residual disease
after 4 cycles of the initial chemotherapy, a
second look surgery may be considered. If second
surgery is performed and there is no detectable
residual disease, the patient will receive
radiation therapy. If there is residual tumor
detected either by an MRI scan or the presence
of raised tumor markers in the blood or
cerebrospinal fluid after chemotherapy and
second surgery (when performed), the patient
will receive an additional regimen of two cycles
of dose-intensified chemotherapy (Cyclophosphamide
and Carboplatin) administered with the support
of healthy peripheral blood stem cells.
Treatment Type:
Chemotherapy
Rhode Island
Hospital
Sam W. Lew, MD
Providence, RI 02903
Phone: 401-444-5171
|
